ResearcherUniversity of LouisvilleActive in the last 2 years

Geoffrey J. Clark

ORCID-verified (high confidence)As of 14 November 2026

Matched on ORCID iD 0009-0001-6750-5682; OpenAlex author ID A5034081771; NIH RePORTER profile ID 8801334.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 1 (first author 0, last author 1)
Pancreatic cancer trials: 0
Pancreatic cancer grants: 1
Labs led: 1
Collaborators: 1

Papers, trials and grants by year

2019: 1 grant · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 1

RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis. Last author DOI 10.1016/j.jbc.2025.110809 ↗

Grants 1

NOVEL PAN-RALGEF INHIBITORS TO BLOCK PANCREATIC CANCER. R21CA216722 ↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Howard Donninger · 1 shared paper, 2025
- Paper RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis. DOI 10.1016/j.jbc.2025.110809 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.